<DOC>
	<DOC>NCT01207752</DOC>
	<brief_summary>The aim of this study will be to determine the efficacy of this novel, lipid-containing artificial tear on the signs and symptoms of meibomian gland disease.</brief_summary>
	<brief_title>The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Schein symptom score (all 6 questions) of greater than 5, evidence of MGD changes in both eyes (i.e., lower eyelid secretion quality score greater than 1.0 (0 3 scale) OR gland dropout score greater than 1.0 (i.e., greater than 25% of entire lower eyelid) as demonstrated by meiboscopy, and corneal staining of grade 4.0 or greater (0 20 scale). contact lens wear, use of topical ocular medication other than artificial tears (use of Restasis is specifically excluded), unstable systemic medication use (i.e., antihistamines, steroids, etc.), recent (within 6 months of study start) ocular trauma or surgery, diabetes, aqueous deficient dry eye (defined as a Schirmer I value (without anesthetic) of &lt; 5 mm of wetting in 5 minutes in either eye), and use of punctal plugs. Subjects taking omega 3 fatty acid supplements for dry eye can be included so long as their intake is stable for the prior six months and they meet the inclusion criteria above.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>dry eye, meibomian gland dysfunction, tear film break up time</keyword>
</DOC>